Trial Profile
Phase I Study of the Fully Human Anti-Epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody IMC-11F8 in Patients With Solid Tumors Who Have Failed Standard Therapy
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Necitumumab (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Eli Lilly and Company; ImClone Systems
- 08 Dec 2008 New trial record.